Investigating how alcohol use disorder medications affect the sense of smell
Olfactory targets of alcohol use disorder medications
This study is looking at how a hormone called oxytocin might help people with alcohol use disorder by reducing their cravings and drinking, and it’s for anyone who wants to learn about new ways to manage their alcohol consumption.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10946292 on NIH RePORTER |
What this research studies
This research explores the effects of oxytocin, a hormone, on alcohol consumption and cravings in individuals with alcohol use disorder. By administering oxytocin intranasally, the study aims to understand how it interacts with the brain's olfactory system to potentially reduce alcohol intake. The researchers will investigate the mechanisms behind oxytocin's effects, particularly focusing on specific brain areas that are involved in the sense of smell and alcohol behavior. This innovative approach seeks to develop more effective treatments for alcohol use disorder.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcohol use disorder who are seeking new treatment options.
Not a fit: Patients who do not have alcohol use disorder or those who are not interested in pharmacological treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for individuals struggling with alcohol use disorder.
How similar studies have performed: Previous studies have shown promising results with oxytocin in reducing alcohol consumption in animal models, but this approach is still being explored in humans.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Ryabinin, Andrey E — Oregon Health & Science University
- Study coordinator: Ryabinin, Andrey E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.